BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8801698)

  • 1. [Costs and effects of alternative screening programs against cervical cancer].
    Gyrd-Hansen D; Hølund B; Andersen P
    Ugeskr Laeger; 1996 Aug; 158(35):4912-5. PubMed ID: 8801698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
    Ginsberg GM; Edejer TT; Lauer JA; Sepulveda C
    Vaccine; 2009 Oct; 27(43):6060-79. PubMed ID: 19647813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?
    Anderson R; Haas M; Shanahan M
    Aust N Z J Public Health; 2008 Feb; 32(1):43-52. PubMed ID: 18290913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effectiveness analysis of cervical cancer screening: health policy implications.
    Gyrd-Hansen D; Hølund B; Andersen P
    Health Policy; 1995 Oct; 34(1):35-51. PubMed ID: 10151964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
    Kim JJ; Leung GM; Woo PP; Goldie SJ
    J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan.
    Koong SL; Yen AM; Chen TH
    J Med Screen; 2006; 13 Suppl 1():S44-7. PubMed ID: 17227642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands.
    Coupé VM; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J
    Vaccine; 2009 Aug; 27(37):5111-9. PubMed ID: 19567242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of cervical cancer with screening programme in Branicevo District and cost-effectiveness analysis adjusted to the territory of the Republic of Serbia.
    Perovic S
    J BUON; 2009; 14(1):93-6. PubMed ID: 19373953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mathematical models of cervical cancer prevention in the Asia Pacific region.
    Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
    Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
    Wong G; Howard K; Webster A; Chapman JR; Craig JC
    Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of multiple disease screening in Keelung: a model for community involvement in health interventions?
    Wang PE; Wang TT; Chiu YH; Yen AM; Chen TH
    J Med Screen; 2006; 13 Suppl 1():S54-8. PubMed ID: 17227644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of screening programs using single and multiple birth cohort simulations: a comparison using a model of cervical cancer.
    Dewilde S; Anderson R
    Med Decis Making; 2004; 24(5):486-92. PubMed ID: 15358997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
    Suba EJ; Nguyen CH; Nguyen BD; Raab SS;
    Cancer; 2001 Mar; 91(5):928-39. PubMed ID: 11251944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chapter 19: Cost-effectiveness of cervical cancer screening.
    Goldie SJ; Kim JJ; Myers E
    Vaccine; 2006 Aug; 24 Suppl 3():S3/164-70. PubMed ID: 16950004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The significance of organized screening for uterine cervix cancer in Denmark during 1968-1987].
    Lynge E; Engholm G; Madsen M
    Ugeskr Laeger; 1992 May; 154(19):1330-4. PubMed ID: 1598705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
    Mennini FS; Giorgi Rossi P; Palazzo F; Largeron N
    Gynecol Oncol; 2009 Feb; 112(2):370-6. PubMed ID: 19041125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
    Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
    Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands.
    Rogoza RM; Westra TA; Ferko N; Tamminga JJ; Drummond MF; Daemen T; Wilschut JC; Postma MJ
    Vaccine; 2009 Jul; 27(35):4776-83. PubMed ID: 19539578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy.
    Kim JJ; Kobus KE; Diaz M; O'Shea M; Van Minh H; Goldie SJ
    Vaccine; 2008 Jul; 26(32):4015-24. PubMed ID: 18602731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.